Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
193
-
Total 13F shares, excl. options
-
93.3M
-
Shares change
-
-5.28M
-
Total reported value, excl. options
-
$1.1B
-
Value change
-
-$28.4M
-
Put/Call ratio
-
0.65
-
Number of buys
-
95
-
Number of sells
-
-75
-
Price
-
$11.83
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q4 2022
240 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q4 2022.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 193 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.3M shares
of 159M outstanding shares and own 58.74% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (15.5M shares), STATE STREET CORP (10.4M shares), BlackRock Inc. (9.13M shares), FMR LLC (7.19M shares), MILLENNIUM MANAGEMENT LLC (6.19M shares), MAVERICK CAPITAL LTD (4.32M shares), WELLINGTON MANAGEMENT GROUP LLP (3.43M shares), ALKEON CAPITAL MANAGEMENT LLC (3.04M shares), GEODE CAPITAL MANAGEMENT, LLC (2.59M shares), and Woodline Partners LP (2.56M shares).
This table shows the top 193 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.